BEIJING, Sept. 30, 2010 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced the Company held its annual general meeting at 9 a.m. Beijing time on September 30, 2010. Each of the proposals submitted for shareholder approval was approved.
The primary resolutions approved were to re-elect Mr. Huining Cao as the Company's director and to appoint Ernst & Young Hua Ming as the independent auditor of the Company for the fiscal year ending December 31, 2010.
About China Nuokang Bio-Pharmaceutical Inc.
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hospital-based medical products. The Company provides a diversified portfolio of products across more than 2,400 hospitals in China. Nuokang's principal products include Baquting®, China's leading hemocoagulase product by market share, and Aiduo®, a cardiovascular stress imaging agent. The Company's product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. Please visit www.nkbp.com for more information.
CONTACT: ICR, LLC In the U.S.: Ashley M. Ammon Christine Duan 1-646-277-1227 In China: Wen Lei Zheng 86-10-6599-7968
